Decitabine
- Atc Codes:L01BC08
- CAS Codes:2353-33-5
- PHARMGKB ID:2353-33-5
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Inhibits
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Greece: Dacogen.
North America
USA: Dacogen.
Latin America
Argentina: Dacogen.
Drug combinations
Chemistry
Decitabine: C~8~H~12~N~4~O~4~. Mw: 228.21. (1) 1,3,5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-; (2) 4-Amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-s-triazin-2(1H)-one; (3) 5-Aza-2′-deoxycytidine. CAS-2353-33-5 (1989).
Pharmacologic Category
Antineoplastic Agents; Antimetabolites; DNA Methyltransferase Inhibitor. (ATC-Code: L01BC08).
Mechanism of action
Synthetic nucleoside analog of 2′-Deoxycytidine. After phosphorylation, decitabine is incorporated into DNA and inhibits DNA methyltransferase causing hypomethylation and subsequent cell death.
Therapeutic use
Treatment of myelodysplastic syndrome. Designated an orphan drug by the FDA for use in this condition.
Pregnancy and lactiation implications
Teratogenic effects in animal studies. Males should avoid fathering a child during therapy and for 2 months after. Pregnancy should be avoided during therapy. Not recommended during lactation.
Unlabeled use
Treatment of acute myelogenous leukemia, chronic myelogenous leukemia, or sickle cell anemia.
Contraindications
Hypersensitivity to decitabine or any component of the formulation.
Warnings and precautions
Bone marrow suppression (anemia, severe neutropenia, and severe thrombocytopenia) is the most common cause of decitabine dosage delay, reduction, or discontinuance. Caution in hepatic or renal impairment (use not studied). Infectious complications reported in clinical trials.